Enliven Therapeutics will feature an encore presentation of data from its ENABLE Phase 1b clinical trial evaluating ELVN-001 at the Society of Hematologic Oncology Annual Meeting at SOHO 2026.

Enliven Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics to help people not only live longer, but live better. Enliven aims to address existing and emerging unmet needs with a precision medicine approach that improves survival and enhances overall well-being. Enliven's discovery process combines deep insights into clinically validated biological targets and differentiated chemistry to design potentially first-in-class or best-in-class therapies.